Lithium decreases plasma adiponectin levels in bipolar depression

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Lithium is a primary treatment for bipolar disorder (BD).
• Significant weight gain is a common side effect of lithium, but underlying mechanisms are unclear.
• Adipokines, such as adiponectin, leptin, and resistin, are implicated in metabolic and inflammatory processes.

Purpose of the Study:

• To investigate the effect of lithium monotherapy on adipokine levels in acutely depressed bipolar disorder patients.
• To explore the relationship between adipokine levels and treatment response.
• To understand the role of adipokines in lithium-induced weight gain and associated comorbidities.

Main Methods:

• Assessed adiponectin, resistin, and leptin levels in 25 acutely depressed BD individuals and 23 healthy controls.
• Measurements were taken at baseline and after 6 weeks of lithium therapy.
• Depression severity was assessed using the Hamilton Depression Rating Scale.

Main Results:

• Adiponectin levels significantly decreased after 6 weeks of lithium monotherapy.
• Resistin and leptin levels remained stable during the study period.
• No significant differences in adipokine levels were observed between BD patients and controls during depressive episodes.
• Pretreatment leptin levels were higher in patients who remitted, and changes in resistin correlated negatively with symptom improvement.

Conclusions:

• Lithium therapy is associated with a decrease in adiponectin levels.
• Adipokine profiles may play a role in the pathophysiology of BD and lithium's side effects.
• Findings suggest potential links between adipokines, metabolic syndrome, inflammation, and comorbidities in BD patients treated with lithium.